Slide 1: Stock exchange filing cover letter
26th July 2023 (1) BSE Ltd. (2) National Stock Exchange of India Ltd. Listing Department Listing Department Phiroze Jeejeebhoy Towers Exchange Plaza, 5th floor Dalal Street Plot no. C/1, G Block Mumbai 400 001 Bandra Kurla Complex Scrip Code: 500087 Bandra (East), Mumbai - 400 051 Scrip Code: CIPLA
Slide 2: Investor Presentation Q1FY24
Investor Presentation Q1FY24 26-07-2023 1
Slide 3: Disclaimer
DISCLAIMER Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results t
Slide 4: Key Highlights: Q1FY24 revenue up 18% YoY
Q1FY24 : Revenue up YoY by 18%; Margin expansion YoY by 230+ bps Stellar Performance across all markets KEY HIGHLIGHTS Global Revenue EBITDA Margin R&D Investment1 23.6% 233 bps 18% (YoY) 5.5% 27% INR 6,329 Cr Reported 31% of overall YoY growth YoY growth revenue Reported YoY growth BUSINESS PERFORM
Slide 5: Financial Performance – Q1FY24
Financial Performance – Q1FY24 Revenues INR 6,329 Cr EBITDA INR 1,494 Cr Revenue1 Break-up Q1FY24 (Consolidated) Actuals API, 2% Others, 1% vs Q1 FY23 (INR Cr) International Markets, Total Revenue from 6,329 17.7% 12% Operations EBITDA 1,494 30.7% SAGA, 12% EBITDA % 23.6% 233 bps India, 44% PAT 996
Slide 6: Healthy Cash position – Continued focus on building balance sheet strength
Healthy Cash position – Continued focus on building balance sheet strength INR Cr Total Debt1 Cash Balance2 Net Cash3 6,138 6,941 5,469 6,273 803 803 Mar'23 Jun'23 Mar'23 Jun'23 Mar'23 Jun'23 1. Total debt includes lease liabilities | 2. Includes cash and cash equivalents including fixed deposits, c
Slide 7: One India: Double digit growth continues
One India1 : Double digit growth continues; Robust growth trajectory across businesses One India business TTM revenue trend Branded Prescriptions : Focused on making Big Brands INR Cr Bigger Ex-covid 10,162 8,964 • Sustained momentum across therapies in core portfolio 7,726 driven by pricing and new
Slide 8: India Branded Prescription; market beating growth continues
India Branded Prescription; market beating growth continues Steady uptake in Chronic portfolio Rank Cardiac 11.1% 5th 11.8% Respiratory 13.5% 1st 16.3% 12.1% Overall Chronic 15.6% 2nd 10.6% IPM 12.4% 3rd YoY expansion in Market Growth Cipla Growth chronic share Anti-Diabetic climbing the growth ladd
Slide 9: Global consumer wellness franchise
Global consumer wellness franchise : Enhance business and improve health 16% 16% Q1 YoY franchise growth Q1 YoY franchise growth One India Consumer brands in SA OTC India Cough, cold & flu Pain relief Hydration INR 385 Cr Cough, cold & flu INR 75+ Cr ZAR 40+ Mn ZAR ~40 Mn INR 65+ Cr Nicotine Replace
Slide 10: North America: Consistent quarter on quarter growth
North America: Consistent quarter on quarter growth resulting from strong execution on new launches and traction in base business 13th consecutive quarter of growth in revenue over previous year Lanreotide inj. Lenalidomide $ Mn Launch launch 43% 222 10% 204 195 179 160 155 150 141 142 Q1FY22 Q2FY22
Slide 11: North America: Robust momentum in differentiated portfolio
North America: Robust momentum in differentiated portfolio Key Business Highlights North America • Highest ever quarterly revenue $222 Mn with a record-breaking quarterly growth of 43% Q1 FY24 YoY $ Mn Q1 FY24 YoY • With continuous ramp up, Lanreotide market share increased to 18% 222 • Good tractio
Slide 12: ANDA & NDA Portfolio & Pipeline (As on 30th June 2023)
ANDA & NDA Portfolio & Pipeline (As on 30th June 2023) 14 59 9 4 19 8 79 2 1 46 20 8 Approved Tentatively Under Approval ANDAs & NDAs Approved ANDAs & NDAs ANDAs & NDAs Cipla Ltd PEPFAR 1 Invagen Partnered ANDAs/NDAs 161 1 31 77 269 Approved Tentatively Under Approval Total ANDAs & NDAs Approved AND
Slide 13: SAGA: Cipla moves to #2 in SA Private Rx Market
SAGA1: Cipla moves to #2 in SA Private Rx Market ZAR Mn Q1 YoY comparison South Africa 318 230 Cipla is now SA Private SA OTC 833 939 market 9 New market Ranked #2 Q1 FY 23 Q1 FY 24 13% launches in 16% In Private Rx (Q1 YoY growth Q1 FY24 (Q1 YoY growth Market2 in ZAR Terms) in ZAR Terms) SA Private
Slide 14: International Markets & API
International Markets & API International Markets API Q1 FY24 Revenue $ Mn Q1 FY24 Revenue $ Mn 95 93 17 17 Q1FY23 Q1FY24 Q1FY23 Q1FY24 Key Business Highlights Key Business Highlights Revenue growth by 9% (Ex-Covid) in INR Terms; where in our Europe Market has reported YoY Consistent growth in e
Slide 15: ESG Update
ESG Update Progress on ESG- FY 23 highlights Recognition for ESG Excellence Award by BW 1.25 % reduction in total energy consumption 27% Renewable Energy in the energy mix 6% reduction in absolute scope 1 and scope 2 GHG emission 4.8% reduction in freshwater withdrawal Cipla received following recog
Slide 16: Profit and Loss statement summary
Profit and Loss statement summary Q1 FY24 Q1 FY23 Particulars (INR Cr) (INR Cr) Revenue from sale of products 6,269 5,318 Other operating income 60 57 Income from operations 6,329 5,375 Material cost 2,237 2,024 Employee benefits expense 1,067 956 Other expenses 1,532 1,252 Total expenses 4,835 4,23
Slide 17: Thank You
Thank You Registered Office : Cipla Limited, Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400 013 For any queries, please contact Ajinkya Pandharkar Investor.Relations@cipla.com Diksha Maheshwari Investor.Relations@cipla.com For more information please visit www.ci